Jorik van Rijn
Hunting for new immunotherapy targets in pediatric T-cell leukemia
Contact details
For one in five children with T-cell acute lymphoblastic leukemia (T-ALL), the current chemotherapy treatment is not effective. For those relapsed/refractory patients, no other curative treatments now exist. My primary goal is to develop a new therapy for these high-risk T-ALL patients based on the recently successful Chimeric Antigen Receptor (CAR) T-cell technology. In addition, I aim to test if this potential therapy could be used to treat other T-cell malignancies, and I hope to learn more about the maturation of healthy T-cells in the process.
- Publications